

Illumina unveils DRAGEN version 4.4 software focusing on oncology applications for clinical research

14 May 2025 | News

Making bioinformatics even easier for complex oncology workflows and multiomics analysis



US-based Illumina Inc. has announced the launch of DRAGEN version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays.

Additionally, DRAGEN v4.4 continues DRAGEN's best-in-class accuracy with a 30% improvement in germline structural variant calling accuracy. DRAGEN v4.4 enhancements will simplify next-generation sequencing NGS analysis for customers while expanding their capabilities.

Providing labs with ready-to-use analysis applications simplifies oncology biomarker detection and reduces complexities for customers. The applications integrate with the Illumina Connected Insights platform, allowing for a fully streamlined analysis and interpretation workflow, and enabling efficient and complete discovery and clinical research solutions across a wide range of customer segments, including genetic disease, oncology, multiomics, infectious disease, and population genomics.

The University Hospital of Tübingen (UHT) in Germany is among the first adopters of the latest version of DRAGEN. UHT researchers have selected DRAGEN for a first-of-its-kind study to evaluate the clinical utility of advanced secondary analysis on whole-genome germline testing. Germline testing can help identify inherited genetic mutations that increase an individual's risk of developing certain cancers or other health conditions.